The mechanism could be the ability of IL-7 to restore the naïve T cell pool through increased survival signals or through more homeostatic proliferation (Figure 2); this was also confirmed in clinical trial of rhIL-7 treatment for refractory cancer patients (3). This evidence concerns the gene IL7 and cancer.